Seeking Alpha

Cytori Therapeutics, Inc. (CYTX)

()

Instablog posts on CYTX

  • Don't Buy In to the Momentum by Jay Springate
    CYTX is up more than 80% since mid-Nov on growing excitement related to the company’s Celution System – primarily used for breast augmentation and reconstruction procedures. Celution separates and concentrates patients’ stem and regenerative cells from adipose fat tissue. Fat... More »
    December 16, 2009 • CYTX
  • Monday's Hot Stocks on Heavy Volume by Marco Hickey
    With the markets trading slightly higher Monday, there were 19 stocks that hit my radar trading higher on much more action. As always, the first thing I do is scan the list for familiar names, such as stocks which have appeared on similar scans multiple times in the past week or two (most of... More »
    December 1, 2009 • DIA, SPY, QQQQ
  • Monday's Rx-Recap (11-02-09) by M. E. Garza
    Below is a list of the healthcare sector companies that made news in the healthcare sector on Monday, November 2, 2009. This list feature is meant to help investors keep tabs on the sector without having to scour through all the press releases.Bristol-Myers Squibb (NYSE:BMY) announced 48-week... More »
    November 3, 2009 • DNDN, GTXI, CYTX
  • CYTORI (CYTX): A STEM CELL HOPE FOR URINARY INCONTINENCE by Prohost Biotech
    A study was led by Momokazu Gotoh, MD, Ph.D., Professor and Chairman of the Department of Urology and Tokunori Yamamoto, MD, Ph.D., Associate Professor Department of Urology at Nagoya University Graduate School of Medicine demonstrate that stem and regenerative cells from a patient’s own... More »
    October 21, 2009 • CYTX
  • A mixed bag for traders and investors in healthcare by M. E. Garza
    As futures for the Dow Jones industrial average, the S&P 500 and the Nasdaq 100 are all pointing to a higher opening on Monday, it's important to note that we are starting a busy week of earnings, and that could be a mixed bag for traders and investors. Last week, the five day trading... More »
    October 12, 2009 • ACOR, SPPI, CYTX
  • Cytori Therapeutics Soars in 2009 by Morgan Myrmo
     I was considering investing in a small, San Diego biotech firm called Cytori Therapeutics (NASDAQ: CTYX) when the stock was about $1.75-1.80 per share this April (2009).  They have a clinical trial in Japan right now where they have used a type of proprietary... More »
    July 12, 2009 • CYTK, AGEN, PPHM
  • FDA, Clinical Trial Updates: JNJ, INCY, MEDX, CYTX, AGN, PPHM by Mike Havrilla
    Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars. The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision... More »
    May 28, 2009 • BAYRY.PK, JNJ, INCY
  • Stem Cell Index Surges in Past Week by Mike Havrilla
    The stem cell trade was back in a big way over the past week, with several stocks in the ETF Innovators Stem Cell Index registering impressive gains, compared to market and biotech ETF benchmarks such as the S&P 500 SPDR (NYSE:SPY) +6%, iShares Nasdaq Biotech (NASDAQ:IBB) +2%, SPDR S&P... More »
    May 10, 2009 • CYTX, GERN, NBS
  • BioMedReports.com Most Popular Articles, Reports by Mike Havrilla
    The following are links to the most viewed articles and stock research reports at BioMedReports.com since the site was launched earlier this year:Stock Research Reports - Cytori Therapeutics (CYTX), NIVS IntelliMedia... More »
    April 9, 2009 • CPD, MNTA, EXAS

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.